
SPECIFICATIONS
Excitation:
495nm
Emission:
515 nm
Product code: 3330
product description
ION’s Multidrug Resistance (MDR) Activity kit is an effective solution for detecting MDR1 and MRP1 activity and compounds susceptible to MDR-mediated efflux. ION’s MDR Activity kit is compatible with fluorescence microscopy, flow cytometry, and fluorescence plate readers using FITC/GFP settings.
Calcein AM is a membrane-permeant, non-fluorescent dye that enters cells passively. Once inside the cytosol of cells, intracellular esterases convert it to fluorescent Calcein (Ex/Em: 495 nm/515 nm), resulting in uniform cytosolic fluorescence. Drug efflux transporters, such as P-glycoprotein (Pgp, MDR1) and multidrug-resistance-associated protein (MRP1), actively extrude Calcein AM from inside the cell before esterases can convert it to Calcein. The presence of additional MDR substrates or inhibitors of MDR expression results in decreased Calcein AM efflux, causing a measurable increase in intracellular fluorescence. In addition to identifying MDR substrates and inhibitors, this kit can also be used to evaluate the activity of MDR transporters in cells.
When following our protocol, ION’s MDR Activity kit provides enough reagents to make 100 mL of working solution, enough for ten 96- or 384-well plates or 80 flow cytometry samples. The actual number of assays will vary according to optimal dye concentrations for your application.

documentation

References
Eilers M, et. al. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir, and zidovudine, from human endothelial cells. Exp Biol Med (Maywood). (2008). 233(9).
Jakab K, et. al. Application of flow cytometry immunophenotyping and multidrug resistance assay in B-cell acute lymphoid leukemia and multiple myeloma. Neoplasma. (2005). 52(1).
Legrand O, et. al. Pgp and MRP Activities Using Calcein-AM Are Prognostic Factors in Adult Acute Myeloid Leukemia Patients. Blood. (1998). 91(12).
Ansbro MR, et. al. Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference. PLoS One. (2013). 8(4).